Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

Advances in RA treatment require improved understanding of patient-specific therapy appropriateness, focusing on disease pathogenesis and heterogeneity. Current RA treatment algorithms lack biomarkers ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

RA is an autoimmune disease where the immune system mistakenly attacks the lining of joints, causing inflammation and potential joint damage. Treatment goals for RA include reducing inflammation and ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

The results of research by scientists at Trinity College Dublin and St. Vincent’s University Hospital offer new insights into the cellular and genetic features of joint inflammation in rheumatoid ...

Treatments and outcomes for rheumatoid arthritis (RA) have made major advances in the last decade. Earlier diagnoses, better treatment strategies, and improvements in disease modifying anti-rheumatic ...

A new study, completed by researchers at Columbia University in New York and Brigham and Women’s Hospital in Boston, suggests that some drugs used to treat rheumatoid arthritis (RA) may also help ...

Quest Diagnostics is partnering with a Massachusetts-based precision immunology company to expand access to diagnostic services for patients with rheumatoid arthritis (RA). Under the multiyear ...